Covid-19 Update to QAA No. 9 - Switching from intravenous to subcutaneous infliximab

27th Apr 2020

The RDTC has updated COVID-19 QAA No. 9 - Switching from intravenous to subcutaneous infliximab. Changes to this version include updating to mirror updates to NICE NG167: COVID-19 rapid guideline - rheumatological autoimmune, inflammatory and metabolic bone disorders to include switching from an intravenous treatment to a subcutaneous form of the same treatment.